Entropy Neurodynamics Files US Patent Backed by 75% IBS Response Rate

Patent Filing Anchored in Strong Clinical Data

Entropy Neurodynamics (ASX:ENP) has taken a significant step to protect its psychedelic-assisted therapy program for irritable bowel syndrome (IBS) by filing a new US provisional patent application. This move follows the release of Phase 2a clinical data for its oral psilocybin candidate TRP-8802, which demonstrated a striking 75% response rate in treatment-resistant IBS patients. This clinical outcome notably outperforms existing therapies, which typically yield response rates between 17% and 44%, marking one of the strongest signals ever reported in IBS drug development.

The patent filing, numbered 64/055,765, builds on Entropy’s earlier international patent application under the Patent Cooperation Treaty (PCT) filed in January 2024. Together, these filings create multiple patent families that cover foundational concepts and new therapeutic insights derived from clinical data. This expanded intellectual property (IP) architecture is designed to protect both oral and intravenous (IV) delivery methods of psychedelic therapies targeting gut-brain disorders.

Complementing Existing IP and Clinical Programs

The new US patent application complements the company’s Australian patent granted in February 2026, which covers a novel, precision-controlled method of administering psilocybin and psilocin. This Australian patent underpins Entropy’s lead asset TRP-8803, an IV-infused psilocin formulation, and secures IP protection through to 2042. The IV formulation aims to address limitations of oral psilocybin by enabling faster onset, controlled depth and duration of the psychedelic experience, and a commercially viable treatment timeframe.

Entropy’s CEO Jason Carroll emphasised the strategic importance of the filing, stating it "materially strengthens Entropy’s IP position at a critical inflection point in clinical development" and is grounded in robust human clinical data. Carroll highlighted that the expanded IP position supports the company’s US-focused development and partnering ambitions, positioning Entropy as a leader in the emerging field of gut-brain targeted psychedelic therapies.

Clinical and Commercial Implications

The Phase 2a results, presented at Digestive Disease Week 2026 by researchers from Massachusetts General Hospital and Columbia University, validate Entropy’s gut-brain axis approach to treating IBS. The data also provide a strong rationale for advancing TRP-8803, which is currently in clinical development for multiple indications including IBS, Binge Eating Disorder, and Fibromyalgia. Early clinical trials have shown promising therapeutic benefits of psychedelic therapy, which will inform the ongoing refinement of TRP-8803.

This filing follows recent progress in Entropy’s Binge Eating Disorder trial with TRP-8803, where early dosing results have demonstrated controlled psychedelic responses and symptom improvements, reinforcing the potential of the IV formulation to deliver reproducible effects. The company’s expanding patent portfolio, including the latest US provisional application, enhances its competitive moat and supports potential licensing or partnering deals in the sizeable US market.

Engaging Investors Amidst Clinical Advances

Entropy is hosting an investor webinar on 6 May 2026, led by CEO Jason Carroll, to discuss these developments and answer questions. This event offers an opportunity for investors to gain insight into the company’s clinical progress and IP strategy at a pivotal stage.

As Entropy advances its TRP-8803 program, the company faces the typical biotech challenges of patent grant uncertainty and the need for further clinical validation. However, the strong Phase 2a data and layered patent protection provide a solid foundation for its US development ambitions and potential market impact.

Investors will be watching how Entropy leverages this expanded IP position alongside upcoming clinical milestones to build value in the competitive psychedelic therapeutics landscape.

These developments build on the company’s recent 75% response rate in treatment-resistant IBS and the ongoing early clinical outcomes from its intravenous psilocin trials, underscoring the clinical and commercial momentum behind its lead assets.